Haptoglobin and Glutamine Synthetase May Biomark Cachexia Induced by Antiacute Myeloid Leukaemia Chemotherapy
Haptoglobin und Glutamin-Synthetase könnten Cachexie durch eine Chemotherapie bei akuter myeloischer Leukämie biomarkieren
Journal of Cachexia, Sarcopenia and Muscle · 2025-06 · 16 (3)
DOI: 10.1002/jcsm.13849 ↗Auf einen Blick
Bei Mäusen führte das AML-Chemotherapieregime zu akuter Cachexie mit Verlust von Körper-, Lean- und Fettmasse sowie Muskelatrophie. Haptoglobin und Glutamin-Synthetase waren im Muskel erhöht.
Fragestellung
Verursacht das Induktionsschema der AML-Chemotherapie bei Mäusen Cachexie und lassen sich dazu Biomarker im Muskel identifizieren?
Methode
3 Monate alte männliche Balb/c-Mäuse erhielten Daunorubicin und Cytarabin oder Vehikel; Analyse an Tag 8, nach 2 Wochen Erholung oder mit Laufradzugang. Proteomik per LC–MS/MS.
Ergebnisse
Akut: ~10 % weniger Körpermasse, ~10 % weniger Lean-Mass und ~20 % kleinere Muskelfasern. Stoffwechsel und Aktivität sanken. Die Cachexie bestand nach 2 Wochen fort; aktive Tiere verloren mehr Fettmasse.
Schlussfolgerung der Autor:innen
Das AML-CIR löst eine akute Abnahme von Körper-, Lean- und Fettmasse mit Muskelatrophie, Hypermetabolismus und Katabolismus aus. Haptoglobin könnte als sensitiv reagierender Muskelbiomarker dienen.
Kernaussagen
- ~10 % Verlust von Körper- und Lean-Masse unter dem AML-CIR
- Haptoglobin und Glul waren im Muskel erhöht
- Haptoglobin zeigte Biomarker-Potenzial über verschiedene Bedingungen hinweg
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, online erschienen am 05.06.2025. Verfasst von Dean G Campelj und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Health and Sport, Victoria University, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Cachexia, Leukemia, Myeloid, Acute, Haptoglobins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Anticancer chemotherapy is an underappreciated contributor to cancer cachexia, an often‐irreversible body‐wasting condition that causes 20%–30% of cancer‐related deaths. An obstacle to predicting, monitoring and understanding the mechanisms underlying chemotherapy cachexia is that each cancer (and subtype) is assigned different chemotherapeutic compounds, typically in multiagent regimens. Here, we investigate the chemotherapy induction regimen (CIR) used in the haematological cancer, acute myeloid leukaemia (AML). We hypothesised that the AML CIR would induce cachexia, including loss of lean tissue mass and skeletal muscle atrophy.
Methods
Using an unbiased proteomics approach, we interrogated the underlying molecular mechanisms. Three‐month‐old male Balb/c mice were treated with the AML CIR via intraperitoneal injections of daunorubicin (1.7 mg/kg) on Days 1–3 and cytarabine (33.2 mg/kg) administered on Days 1–7 or vehicle. Mice were assessed 24 h after the last treatment, on Day 8, or allowed to recover for 2 weeks and assessed on Day 22. A third cohort was given access to running wheels in cages. We assessed body composition and whole‐body metabolism and assessed the muscle proteome using quantitative tandem mass tag labelling LC–MS/MS analysis. Data are available via ProteomeXchange with identifier PXD063910.
Results
The AML CIR‐induced acute cachexia involved a ~10% loss of body mass, ~10% loss of lean mass and ~20% reduction in skeletal muscle fibre size. Whole‐body metabolism and ambulatory activity declined. This cachexic phenotype did not recover over the 2‐week post‐CIR period (lean mass loss post‐CIR: 1 week ~7% vs. 2 weeks ~9%). In voluntarily active CIR‐treated mice, body wasting was exacerbated due to unchecked loss of fat mass (CIR sedentary: ~31% vs. CIR active: ~51%). Muscle proteome studies revealed upregulation of haptoglobin (Hp) and glutamine synthetase (Glul), which were positively correlated with body and lean mass loss. Hp was sensitive to the conditional induction, recovery and exacerbation of AML CIR‐mediated cachexia, suggestive of biomarker potential.
Conclusions
The AML CIR induces an acute reduction of body, lean and fat mass underpinned by skeletal muscle atrophy, hypermetabolism and catabolism. Our data uncovered a conditionally sensitive muscle biomarker in Hp, which may be useful as a prognostic tool across other scenarios of chemotherapy‐induced myopathy and cachexia or as a target for therapeutic discovery in follow‐up studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Health and Sport, Victoria University, Melbourne, Victoria, Australia.
- Biology of Ageing Laboratory, Centre for Healthy Ageing, Centenary Institute, Camperdown, New South Wales, Australia.
- Faculty of Medicine and Health, Charles Perkins Centre, University of Sydney, Sydney, Australia.
- Inherited and Acquired Myopathies Program, Australian Institute for Musculoskeletal Science, St Albans, Victoria, Australia.
- Department of Medicine-Western Health, Melbourne Medical School, The University of Melbourne, St Albans, Victoria, Australia.
- Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
ORCID-Profile: Emma Rybalka
Zitieren
APA
Campelj, D. G., Timpani, C. A., Spiesberger, G., Formosa, L. E., Steele, J. R., Zhang, H., Schittenhelm, R. B., Leow, L., Goodman, C. A., & Rybalka, E. (2025). Haptoglobin and Glutamine Synthetase May Biomark Cachexia Induced by Antiacute Myeloid Leukaemia Chemotherapy. Journal of Cachexia, Sarcopenia and Muscle, 16(3). https://doi.org/10.1002/jcsm.13849
Vancouver
Campelj DG, Timpani CA, Spiesberger G, Formosa LE, Steele JR, Zhang H, et al. Haptoglobin and Glutamine Synthetase May Biomark Cachexia Induced by Antiacute Myeloid Leukaemia Chemotherapy. Journal of Cachexia, Sarcopenia and Muscle. 2025;16(3). doi:10.1002/jcsm.13849
BibTeX
@article{Campelj2025,
author = {Campelj, Dean G and Timpani, Cara A and Spiesberger, Guinevere and Formosa, Luke E and Steele, Joel R and Zhang, Haijian and Schittenhelm, Ralf B and Leow, Lewis and Goodman, Craig A and Rybalka, Emma},
title = {Haptoglobin and Glutamine Synthetase May Biomark Cachexia Induced by Antiacute Myeloid Leukaemia Chemotherapy},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2025},
volume = {16},
number = {3},
doi = {10.1002/jcsm.13849}
}
EUVIMED